Twinbeech Capital LP Vertex Pharmaceuticals Inc Transaction History

Twinbeech Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $55 Million - $61.9 Million	192,626 New	192,626 $55.6 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $1.75 Million - $2.06 Million	-7,909 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $10.5 Million - $13.3 Million	-59,347 Reduced 88.24%	7,909 $1.74 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $8.17 Million - $9.15 Million	45,061 Added 203.02%	67,256 $12.2 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $4.16 Million - $4.91 Million	22,195 New	22,195 $4.48 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $1.41 Million - $1.75 Million	-7,050 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $1.18 Million - $1.58 Million	7,050 New	7,050 $1.54 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.